Employee Disputes and Innovation Performance: Evidence from Pharmaceutical Industry
Networks Financial Institute Working Paper Series 2019-WP-01
62 Pages Posted: 2 Aug 2019
Date Written: July 30, 2019
In this study, we use a hand-collected dataset of employee lawsuits to understand the effect of employee allegations on firms’ innovation in a human capital-intensive industry. We gather more than 2,293 employee disputes between 2000 and 2015 and test the relationship between employee lawsuits and Food and Drug Administration (FDA) product approvals in the pharmaceutical industry. We find that employee disputes lower the total number of FDA-approved products. We document that firms with frequent employee allegations maintain low innovation outcomes. Additional results show that case characteristics are an important determinant of FDA approvals; labor unions and case duration delay time-to-approval of submitted products, which may explain the deteriorated innovation outcomes. Overall, our findings highlight the importance of employee treatment in the workplace environment, which is ultimately related to firms’ innovation performance.
Keywords: Institutional Investors, Labor Relations, Innovation
JEL Classification: G30, G39, G23, O32
Suggested Citation: Suggested Citation